C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$2.12 USD
+0.07 (3.41%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CCCC 2.12 +0.07(3.41%)
Will CCCC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCCC
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CCCC
C4 Therapeutics Holds Annual Stockholders Meeting
C4 Therapeutics: An Entry Point If There's Ever Going To Be One
Wasatch Ultra Growth Fund Q1 2025 Commentary
C4 Therapeutics Reports Q1 2025 Financial Results
C4 Therapeutics (CCCC) Exceeds Revenue Expectations and Advances Key Drug Development | CCCC ...